Connection

Robert Harrington to Randomized Controlled Trials as Topic

Back to Details
This is a "connection" page, showing publications Robert Harrington has written about Randomized Controlled Trials as Topic.
Robert Harrington
Connection Strength
4.282
Randomized Controlled Trials as Topic
  1. Trials and Tribulations of Randomized Clinical Trials. Circulation. 2022 Aug 02; 146(5):380-382.
    View in: PubMed
    Score: 0.603
  2. When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials. Am Heart J. 2017 07; 189:1-8.
    View in: PubMed
    Score: 0.419
  3. Transforming clinical trials in cardiovascular disease: mission critical for health and economic well-being. JAMA. 2012 Nov 07; 308(17):1743-4.
    View in: PubMed
    Score: 0.309
  4. Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. Int J Cardiol. 2013 Jul 31; 167(2):548-54.
    View in: PubMed
    Score: 0.294
  5. Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. JAMA Netw Open. 2021 07 01; 4(7):e2117963.
    View in: PubMed
    Score: 0.141
  6. Randomized Trials Versus Common?Sense and Clinical Observation: JACC Review Topic of the Week. J Am Coll Cardiol. 2020 08 04; 76(5):580-589.
    View in: PubMed
    Score: 0.132
  7. Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. Blood Cells Mol Dis. 2018 09; 72:37-43.
    View in: PubMed
    Score: 0.115
  8. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. Am Heart J. 2018 07; 201:124-135.
    View in: PubMed
    Score: 0.113
  9. The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease. J Am Coll Cardiol. 2016 10 25; 68(17):1898-1907.
    View in: PubMed
    Score: 0.102
  10. Coronary Artery Bypass Surgery Is Not Underutilized! Circulation. 2016 Mar 08; 133(10):1027-35.
    View in: PubMed
    Score: 0.097
  11. Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials. Circulation. 2016 Apr 19; 133(16):1560-73.
    View in: PubMed
    Score: 0.097
  12. No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. Int J Cardiol. 2014 Sep; 176(1):300-2.
    View in: PubMed
    Score: 0.087
  13. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials. Circ Cardiovasc Qual Outcomes. 2011 Jul; 4(4):448-58.
    View in: PubMed
    Score: 0.070
  14. Premature release of data from clinical trials of ezetimibe. N Engl J Med. 2009 Aug 13; 361(7):712-7.
    View in: PubMed
    Score: 0.062
  15. Comparative effectiveness of angiotensin-converting-enzyme inhibitors: is an ACE always an ace? CMAJ. 2008 May 06; 178(10):1316-9.
    View in: PubMed
    Score: 0.057
  16. International variation in the use of blood transfusion in patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol. 2008 Jan 01; 101(1):25-29.
    View in: PubMed
    Score: 0.055
  17. Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials. Eur Heart J. 2007 Feb; 28(4):425-32.
    View in: PubMed
    Score: 0.052
  18. Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction. Am Heart J. 2006 Feb; 151(2):316-22.
    View in: PubMed
    Score: 0.048
  19. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol. 2006 Feb 21; 47(4):809-16.
    View in: PubMed
    Score: 0.048
  20. The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics. Am Heart J. 2005 Oct; 150(4):643-9.
    View in: PubMed
    Score: 0.047
  21. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005 Nov 01; 96(9):1200-6.
    View in: PubMed
    Score: 0.047
  22. Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes. Am J Cardiol. 2005 Jun 15; 95(12):1404-8.
    View in: PubMed
    Score: 0.046
  23. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale. Am Heart J. 2005 Jun; 149(6):994-1002.
    View in: PubMed
    Score: 0.046
  24. Interventional cardiovascular pharmacotherapy: current issues. Am J Cardiovasc Drugs. 2005; 5(2):93-102.
    View in: PubMed
    Score: 0.045
  25. Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials. Eur Heart J. 2005 Jan; 26(2):128-36.
    View in: PubMed
    Score: 0.045
  26. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):513S-548S.
    View in: PubMed
    Score: 0.044
  27. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J. 2004 Mar; 147(3):457-62.
    View in: PubMed
    Score: 0.042
  28. Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods. Circulation. 2004 Feb 10; 109(5):641-6.
    View in: PubMed
    Score: 0.042
  29. Advances and continued controversy in coronary revascularization of patients with diabetes mellitus. Curr Diab Rep. 2003 Oct; 3(5):351-5.
    View in: PubMed
    Score: 0.041
  30. Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention. Am J Cardiovasc Drugs. 2003; 3(6):423-36.
    View in: PubMed
    Score: 0.039
  31. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Lancet. 2002 Jul 27; 360(9329):342-3.
    View in: PubMed
    Score: 0.038
  32. Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes. Circulation. 2002 Jul 16; 106(3):309-12.
    View in: PubMed
    Score: 0.038
  33. Generating evidence for therapeutic effects: the need for well-conducted randomized trials. J Clin Invest. 2021 01 19; 131(2).
    View in: PubMed
    Score: 0.034
  34. Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019 07; 12(7):e007342.
    View in: PubMed
    Score: 0.031
  35. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clin Cardiol. 2019 May; 42(5):498-505.
    View in: PubMed
    Score: 0.030
  36. Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y12 Inhibitor Pretreatment. Circ Cardiovasc Interv. 2019 03; 12(3):e007445.
    View in: PubMed
    Score: 0.030
  37. Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. J Am Heart Assoc. 2018 12 18; 7(24):e009609.
    View in: PubMed
    Score: 0.029
  38. Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. Am J Hematol. 2019 01; 94(1):21-28.
    View in: PubMed
    Score: 0.029
  39. Planning and Conducting the ISCHEMIA Trial. Circulation. 2018 10 02; 138(14):1384-1386.
    View in: PubMed
    Score: 0.029
  40. Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous?Coronary Intervention. JACC Cardiovasc Interv. 2018 05 14; 11(9):856-864.
    View in: PubMed
    Score: 0.028
  41. Rediscovering the Orbit of Percutaneous Coronary Intervention After ORBITA. Circulation. 2018 06 05; 137(23):2427-2429.
    View in: PubMed
    Score: 0.028
  42. Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). Circ Cardiovasc Interv. 2018 04; 11(4):e005635.
    View in: PubMed
    Score: 0.028
  43. Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. EuroIntervention. 2018 02 02; 13(15):e1841-e1849.
    View in: PubMed
    Score: 0.028
  44. Potent P2Y12 Inhibitors in Men?Versus?Women: A?Collaborative?Meta-Analysis?of?Randomized?Trials. J Am Coll Cardiol. 2017 Mar 28; 69(12):1549-1559.
    View in: PubMed
    Score: 0.026
  45. The Systematic Evaluation of Identifying the Infarct Related Artery Utilizing Cardiac Magnetic Resonance in Patients Presenting with ST-Elevation Myocardial Infarction. PLoS One. 2017; 12(1):e0169108.
    View in: PubMed
    Score: 0.026
  46. Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2017 01; 10(1).
    View in: PubMed
    Score: 0.026
  47. Radial access in patients with acute coronary syndrome without persistent ST-segment elevation: Systematic review, collaborative meta-analysis, and meta-regression. Int J Cardiol. 2016 Nov 01; 222:1031-1039.
    View in: PubMed
    Score: 0.025
  48. Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. Am Heart J. 2016 08; 178:176-84.
    View in: PubMed
    Score: 0.025
  49. Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial. J Am Coll Cardiol. 2016 Feb 09; 67(5):596-8.
    View in: PubMed
    Score: 0.024
  50. Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial. Circulation. 2016 Jan 12; 133(2):131-8.
    View in: PubMed
    Score: 0.024
  51. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth. 2013 Dec; 27(6):1224-32.
    View in: PubMed
    Score: 0.020
  52. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013 Dec 14; 382(9909):1981-92.
    View in: PubMed
    Score: 0.020
  53. Heart failure complicating non-ST-segment elevation acute coronary syndrome: timing, predictors, and clinical outcomes. JACC Heart Fail. 2013 Jun; 1(3):223-9.
    View in: PubMed
    Score: 0.020
  54. A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. Heart. 2013 Sep; 99(17):1282-7.
    View in: PubMed
    Score: 0.020
  55. Incidence and clinical significance of cardiac biomarker elevation during stem cell mobilization, apheresis, and intramyocardial delivery: an analysis from ACT34-CMI. Am Heart J. 2012 Nov; 164(5):689-697.e3.
    View in: PubMed
    Score: 0.019
  56. Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery. Circulation. 2012 Feb 14; 125(6):749-56.
    View in: PubMed
    Score: 0.018
  57. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011 May 31; 123(21):2434-506.
    View in: PubMed
    Score: 0.017
  58. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011 Feb 08; 57(6):672-84.
    View in: PubMed
    Score: 0.017
  59. Sex differences in mortality following acute coronary syndromes. JAMA. 2009 Aug 26; 302(8):874-82.
    View in: PubMed
    Score: 0.015
  60. Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Circulation. 2007 Dec 04; 116(23):2669-77.
    View in: PubMed
    Score: 0.014
  61. The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J Am Coll Cardiol. 2006 Oct 17; 48(8):1567-72.
    View in: PubMed
    Score: 0.013
  62. Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. Am Heart J. 2006 Jul; 152(1):157-63.
    View in: PubMed
    Score: 0.012
  63. Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke. 2006 Jun; 37(6):1427-31.
    View in: PubMed
    Score: 0.012
  64. Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. Eur Heart J. 2006 Mar; 27(5):527-33.
    View in: PubMed
    Score: 0.012
  65. Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):549S-575S.
    View in: PubMed
    Score: 0.011
  66. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004 Jul 07; 292(1):89-96.
    View in: PubMed
    Score: 0.011
  67. Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction. Am Heart J. 2004 May; 147(5):847-52.
    View in: PubMed
    Score: 0.011
  68. Aspirin dose and six-month outcome after an acute coronary syndrome. J Am Coll Cardiol. 2004 Mar 17; 43(6):972-8.
    View in: PubMed
    Score: 0.011
  69. Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol. 2003 Sep 15; 92(6):651-5.
    View in: PubMed
    Score: 0.010
  70. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). Am Heart J. 2002 Dec; 144(6):995-1002.
    View in: PubMed
    Score: 0.010
  71. Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy. J Am Coll Cardiol. 2002 Jun 19; 39(12):1924-9.
    View in: PubMed
    Score: 0.009
  72. The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. Am J Med. 2002 Jun 01; 112(8):647-58.
    View in: PubMed
    Score: 0.009
  73. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002 Jan 19; 359(9302):189-98.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.